JP5592261B2 - ジアミノフェノチアジンの治療的使用 - Google Patents

ジアミノフェノチアジンの治療的使用 Download PDF

Info

Publication number
JP5592261B2
JP5592261B2 JP2010527519A JP2010527519A JP5592261B2 JP 5592261 B2 JP5592261 B2 JP 5592261B2 JP 2010527519 A JP2010527519 A JP 2010527519A JP 2010527519 A JP2010527519 A JP 2010527519A JP 5592261 B2 JP5592261 B2 JP 5592261B2
Authority
JP
Japan
Prior art keywords
dose
compound
mtc
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010527519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540606A5 (enExample
JP2010540606A (ja
Inventor
クロード ミッシェル ウィズチック
デーモン ジュード ウィズチック
ジョン マービン デイビッド ストレー
チャールズ ロバート ハーリントン
Original Assignee
ウィスタ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスタ ラボラトリーズ リミテッド filed Critical ウィスタ ラボラトリーズ リミテッド
Publication of JP2010540606A publication Critical patent/JP2010540606A/ja
Publication of JP2010540606A5 publication Critical patent/JP2010540606A5/ja
Application granted granted Critical
Publication of JP5592261B2 publication Critical patent/JP5592261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2010527519A 2007-10-03 2008-10-01 ジアミノフェノチアジンの治療的使用 Active JP5592261B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96054407P 2007-10-03 2007-10-03
US60/960,544 2007-10-03
PCT/GB2008/003315 WO2009044127A1 (en) 2007-10-03 2008-10-01 Therapeutic use of diaminophenothiazines

Publications (3)

Publication Number Publication Date
JP2010540606A JP2010540606A (ja) 2010-12-24
JP2010540606A5 JP2010540606A5 (enExample) 2011-11-17
JP5592261B2 true JP5592261B2 (ja) 2014-09-17

Family

ID=40220337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527519A Active JP5592261B2 (ja) 2007-10-03 2008-10-01 ジアミノフェノチアジンの治療的使用

Country Status (16)

Country Link
US (3) US9149481B2 (enExample)
EP (2) EP2205245B1 (enExample)
JP (1) JP5592261B2 (enExample)
CN (1) CN101883567B (enExample)
AU (1) AU2008306688B2 (enExample)
BR (1) BRPI0818182B1 (enExample)
CA (2) CA3027974C (enExample)
DK (2) DK2205245T3 (enExample)
ES (2) ES2701089T3 (enExample)
HR (1) HRP20151006T1 (enExample)
HU (1) HUE025199T2 (enExample)
MY (1) MY161656A (enExample)
PL (2) PL2954932T3 (enExample)
PT (2) PT2954932T (enExample)
SI (2) SI2954932T1 (enExample)
WO (1) WO2009044127A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2013191T6 (pl) 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
MY161656A (en) * 2007-10-03 2017-04-28 Wista Lab Ltd Therapeutic use of diaminophenothiazines
SG185094A1 (en) 2010-04-30 2012-12-28 Prostetta Antiviral Inc Antiviral compounds
SG190406A1 (en) 2010-11-30 2013-06-28 Wista Lab Ltd Formulations comprising methylthioninium chloride
ES2714692T3 (es) 2011-01-31 2019-05-29 Tau Bio Logic Corp Tratamiento de tauopatías
PT2673266T (pt) 2011-02-11 2016-10-07 Wista Lab Ltd Sais de fenotiazina diamínio e sua utilização
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
CN103864717B (zh) * 2014-04-04 2015-11-11 山东理工大学 一种针状亚甲基白晶体的制备方法
CN103923036B (zh) * 2014-04-24 2015-09-16 山东理工大学 一种棒状亚甲基蓝晶体的制备方法
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
FI3487505T3 (fi) 2016-07-25 2023-06-05 Wista Lab Ltd Diaminofenotiatsiinien antaminen ja annostus
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
SI3826639T1 (sl) 2018-07-26 2025-01-31 Wista Laboratories Ltd. Optimizirano odmerjanje diaminofenotiazinov v populacijah
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN111956245A (zh) * 2020-08-27 2020-11-20 复旦大学附属肿瘤医院 术后认知功能障碍预防评估方法，系统和装置
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
CN120225180A (zh) 2022-09-21 2025-06-27 维斯塔实验室有限公司 新型制剂及媒剂
WO2024163665A1 (en) * 2023-01-31 2024-08-08 Unlearn.AI, Inc. Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
WO2007056439A1 (en) * 2005-11-08 2007-05-18 Collegium Pharmaceutical, Inc. Salts of methylene blue and its derivatives
PL2013191T6 (pl) * 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
CN101460157B (zh) * 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
MY148145A (en) * 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
HUE045460T2 (hu) * 2007-06-19 2019-12-30 Wista Lab Ltd Fenotiazin vegyületek enyhe kognitív zavar kezelésére
MY161656A (en) * 2007-10-03 2017-04-28 Wista Lab Ltd Therapeutic use of diaminophenothiazines

Also Published As

Publication number Publication date
EP2205245A1 (en) 2010-07-14
DK2954932T3 (en) 2018-12-17
EP2954932B1 (en) 2018-09-19
CN101883567A (zh) 2010-11-10
US20100290986A1 (en) 2010-11-18
US20190151329A1 (en) 2019-05-23
CA2701075C (en) 2019-02-12
WO2009044127A1 (en) 2009-04-09
CA2701075A1 (en) 2009-04-09
CA3027974C (en) 2022-03-15
AU2008306688A1 (en) 2009-04-09
US9149481B2 (en) 2015-10-06
SI2954932T1 (sl) 2019-01-31
CN101883567B (zh) 2012-12-26
BRPI0818182A2 (pt) 2020-06-23
SI2205245T1 (sl) 2015-10-30
CA3027974A1 (en) 2009-04-09
PT2205245E (pt) 2015-10-13
ES2701089T3 (es) 2019-02-20
PL2205245T3 (pl) 2015-12-31
ES2546819T3 (es) 2015-09-28
MY161656A (en) 2017-04-28
AU2008306688B2 (en) 2014-05-22
US20160030444A1 (en) 2016-02-04
PL2954932T3 (pl) 2019-04-30
HUE025199T2 (en) 2016-01-28
DK2205245T3 (en) 2015-09-28
US10188658B2 (en) 2019-01-29
HK1211889A1 (en) 2016-06-03
JP2010540606A (ja) 2010-12-24
EP2205245B1 (en) 2015-06-24
HK1140675A1 (en) 2010-10-22
BRPI0818182B1 (pt) 2021-10-19
EP2954932A1 (en) 2015-12-16
HRP20151006T1 (hr) 2015-10-23
PT2954932T (pt) 2018-12-12

Similar Documents

Publication Publication Date Title
JP5592261B2 (ja) ジアミノフェノチアジンの治療的使用
JP5520043B2 (ja) ３，７−ジアミノ−１０ｈ−フェノチアジン塩およびその使用
AU2022291420B2 (en) Administration and dosage of diaminophenothiazines
ES2659030T3 (es) Compuestos de tioninio y su uso
JP7465861B2 (ja) 集団におけるジアミノフェノチアジンの最適化投与
HK1140675B (en) Therapeutic use of diaminophenothiazines
HK1211889B (en) Therapeutic use of diaminophenothiazines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140731

R150 Certificate of patent or registration of utility model

Ref document number: 5592261

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250